Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$8.90 USD
+0.28 (3.25%)
Updated May 31, 2024 04:00 PM ET
After-Market: $9.14 +0.24 (2.70%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Candel Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 38 | 35 | 26 | 14 | 0 |
Income After Depreciation & Amortization | -38 | -35 | -26 | -14 | 0 |
Non-Operating Income | 3 | 16 | -10 | -4 | NA |
Interest Expense | 3 | 0 | 0 | 0 | NA |
Pretax Income | -38 | -19 | -36 | -18 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -38 | -19 | -36 | -18 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -38 | -19 | -36 | -18 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -37 | -34 | -25 | -14 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 0 | NA |
Income After Depreciation & Amortization | -38 | -35 | -26 | -14 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 28.94 | 28.82 | 18.87 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.31 | -0.65 | -0.41 | NA | NA |
Diluted Net EPS (GAAP) | -1.31 | -0.65 | -1.91 | NA | NA |
Fiscal Year end for Candel Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.90 | 10.32 | 8.87 | 9.58 | 9.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.90 | -10.32 | -8.87 | -9.58 | -9.63 |
Non-Operating Income | 0.33 | 0.51 | 1.10 | 0.61 | 0.84 |
Interest Expense | 0.65 | 1.28 | 0.67 | 0.64 | 0.00 |
Pretax Income | -8.22 | -11.10 | -8.44 | -9.61 | -8.80 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.22 | -11.10 | -8.44 | -9.61 | -8.80 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.22 | -11.10 | -8.44 | -9.61 | -8.80 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 29.20 | 28.98 | 28.92 | 28.92 | 28.92 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.38 | -0.29 | -0.33 | -0.30 |
Diluted Net EPS (GAAP) | -0.28 | -0.39 | -0.29 | -0.33 | -0.30 |